Samsung Biologics shareholders approve spin-off with overwhelming support

Samsung Biologics CEO John Rims speaks out at a shareholders meeting held in Incheon Oct 17 2025 Courtesy of Samsung Biologics — Samsung Biologics CEO John Rims speaks out at a shareholders meeting held in Incheon, Oct. 17, 2025. Courtesy of Samsung Biologics

SEOUL, October 17 (AJP) - Samsung Biologics Co. said on Friday its shareholders voted overwhelmingly to approve a plan to spin off its investment division, with 99.9 percent backing the proposal at an extraordinary general meeting in Incheon.

The approval paves the way for the creation of Samsung Epis Holdings, a pure holding company that will take over the parent's entire stake in biosimilar developer Samsung Bioepis, while Samsung Biologics will remain as the surviving entity focused on its contract development and manufacturing operations.

Shares in Samsung Biologics fell 1.06 percent to 1,121,000 won as of 10:02 a.m. local time.

Kim Dong-young davekim0807@ajupress.com